The Drug Controller General of India approved SII’s anti-cervical cancer vaccine, which follows the institute’s COVID-19 vaccine recommendation, in June last year.
The Drug Controller General of India approved SII’s anti-cervical cancer vaccine, which follows the institute’s COVID-19 vaccine recommendation, in June last year.
Serum Institute of India CEO Adar Poonawalla said on 12 July that the company plans to launch indigenously developed vaccine To prevent cervical cancer in women later this year.
Drugs Controller General of India (DCGI) on July 12 granted market authorization to Serum Institute of India (SII) for manufacturing India’s first indigenously developed quadrivalent Human Papillomavirus Vaccine (QHPV) against cervical cancer.
Responding to the approval by the drug regulator, Mr Poonawalla in a tweet said, “For the first time ever, there will be an Indian HPV vaccine for the treatment of cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank #DCGI @MoHFW_INDIA for approving today.” The approval by the drug regulator of SII’s anti-cancer vaccine follows the recommendation of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for a COVID-19 vaccine on June 15, 2021.
The company had applied to DCGI for market authorization of QHPV after the completion of Phase 2/3 clinical trial with the support of Department of Biotechnology.
Cervical cancer in India is the second most common cancer among women aged 15 to 44 years.
Serum Institute of India to launch vaccine to prevent cervical cancer
The Drug Controller General of India approved SII’s anti-cervical cancer vaccine, which follows the institute’s COVID-19 vaccine recommendation, in June last year.
The Drug Controller General of India approved SII’s anti-cervical cancer vaccine, which follows the institute’s COVID-19 vaccine recommendation, in June last year.
Serum Institute of India CEO Adar Poonawalla said on 12 July that the company plans to launch indigenously developed vaccine To prevent cervical cancer in women later this year.
Drugs Controller General of India (DCGI) on July 12 granted market authorization to Serum Institute of India (SII) for manufacturing India’s first indigenously developed quadrivalent Human Papillomavirus Vaccine (QHPV) against cervical cancer.
Responding to the approval by the drug regulator, Mr Poonawalla in a tweet said, “For the first time ever, there will be an Indian HPV vaccine for the treatment of cervical cancer in women that is both affordable and accessible. We look forward to launching it later this year and we thank #DCGI @MoHFW_INDIA for approving today.” The approval by the drug regulator of SII’s anti-cancer vaccine follows the recommendation of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) for a COVID-19 vaccine on June 15, 2021.
The company had applied to DCGI for market authorization of QHPV after the completion of Phase 2/3 clinical trial with the support of Department of Biotechnology.
Cervical cancer in India is the second most common cancer among women aged 15 to 44 years.